BACKGROUND Patients with protein-losing enteropathy (PLE) following the Fontan operation have a reported 50%
P rotein-losing enteropathy (PLE) occurs in 5% to 15% of patients after the modified Fontan operation and has been a historically difficult complication to treat (1, 2) . PLE is characterized by the enteric loss of proteins such as albumin, immunoglobulins, and clotting factors. The protein loss that occurs leads to the clinical findings of peripheral edema, ascites, diarrhea, weight loss, and malabsorption. The exact mechanisms of this complication are poorly understood, and treatment strategies vary.
Patients with PLE following the Fontan operation have a reported 50% mortality at 5 years after initial diagnosis (1, 2) . Numerous treatment strategies have been used, including medical therapy, such as controlled-release budesonide and sildenafil, as well as interventional and surgical therapies, such as Fontan revision and Fontan fenestration creation (3) (4) (5) (6) . Even with these treatment advances, limited studies have reported improved survival for patients with PLE following the Fontan operation (7) .
The purpose of this study was to determine the survival of patients with PLE following the Fontan operation in the current era. We sought to identify factors associated with patient mortality and to review treatment strategies used in survivors. STATISTICAL ANALYSIS. Continuous variables are expressed as mean AE SD or median (interquartile range) when appropriate. Differences in median age and time intervals from surgery were examined using the Wilcoxon rank-sum test. Frequencies with proportions were determined for categorical variables. Survival curves were generated through Kaplan-Meier analysis and compared using log-rank tests. Laboratory and hemodynamic variables were further analyzed through the chi-square test. The Fisher exact test was used when appropriate to account for small sample size distribution. Due to the small sample size, variables were examined through a univariate analysis only. All statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, North Carolina).
METHODS

RESULTS
PATIENT DEMOGRAPHICS. Forty-two patients with PLE following a Fontan operation were identified.
Patient demographics are summarized in Table 1 . The mean time from diagnosis to last follow-up was 8.4 AE 6 years (range 1 to 22 years). Mean age at follow-up was 26.5 AE 11.6 years (range 5 to 58 years). PATIENT SURVIVAL. Survival was 88% at 5 years after diagnosis of PLE (Fig. 1 ). There were 11 deaths.
Mean age at death was 32 AE 7. All patients with PLE should undergo a comprehensive evaluation, as described in Table 4 . Evaluation is focused on determining both cardiac and noncardiac causes of low cardiac output. Consultation with a gastroenterologist is recommended to rule out other causes of PLE. In addition, evaluation should be performed to rule out other causes of protein loss, such as nephrotic syndrome. Hepatic dysfunction has been increasingly recognized in patients following the Fontan operation (11) . Assessment of hepatic dysfunction is important because certain therapies, such as budesonide, are metabolized through the liver (12) . In addition, bleeding risk may be increased in patients with hepatic dysfunction and should be considered before the initiation of heparin therapy (13) .
Because the cause of PLE can be multifactorial, it is important to individualize the treatment plan for each patient (14) . A thorough, systematic approach is needed to address all possible etiologies. A suggested algorithm for treatment of PLE following the Fontan (52) 5 (45) 21 (50) Fontan conversion* 7 (23) 2 (18) 9 (21) Fontan obstruction relief 7 (23) 2 (18) 9 (21) Ablation therapy 15 (48) 8 (73) Further study is needed to determine the exact mechanism of spironolactone in patients with PLE after the Fontan operation. Octreotide, a somastatin analogue, also was used with some success in our cohort, although the experience is limited (25) .
Octreotide decreases lymphatic flow but does increase gallstone formation. It should not be used as an initial therapy, but as an adjunct in a treatment regimen that targets cardiac and other intestinal etiologies. Further multicenter studies are needed to determine the ideal treatment strategy.
